Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pain’s 17th World Congress on Pain

World News: . []

EVANSTON, Ill., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of two posters highlighting preclinical data on novel N-methyl D-aspartate (NMDA) receptor modulator, NYX-2925, that support its ongoing clinical development for the treatment of chronic pain conditions. Results from the preclinical studies will be presented at the International Association for the Study of Pain’s (IASP) 17 World Congress on Pain in Boston. 

“These compelling preclinical data observed in the course of our ongoing research and discovery efforts demonstrate strong mechanistic support for developing NYX-2925 as a potential therapy for chronic pain conditions, in which synaptic plasticity processes are known to be disrupted,” said Cassia Cearley, PhD, vice president of research at Aptinyx. “These data show that NYX-2925 has the potential to address not only the pain, but also the emotional and cognitive impairments that often result from synaptic plasticity disruption.”

NYX-2925 has demonstrated robust activity in preclinical models of numerous neuropathic pain conditions with a favorable tolerability profile. In a Phase 1 clinical study in healthy human subjects, NYX-2925 was well tolerated across a wide dose range, including dose levels well in excess of the expected therapeutic levels. NYX-2925 is currently in Phase 2 clinical development for the treatment of painful diabetic peripheral neuropathy (DPN) and is also being evaluated in an exploratory Phase 2 study in fibromyalgia. The U.S. Food and Drug Administration has granted Fast Track designation to Aptinyx’s development of NYX-2925 for the treatment of neuropathic pain associated with DPN. 

Investor Contacts:Nick SmithAptinyx Inc.847-871-0377

Rachel FrankStern Investor Relationsrachelf@sternir.com212-362-1200

Media Contact:Jordann PhillipsCanale Communications619-849-6009


More news and information about Aptinyx Inc.

Published By:

Globe Newswire: 13:07 GMT Friday 14th September 2018

Published: .

Search for other references to "aptinyx" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us